Section of Hematology / Oncology
Assistant Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730
|BS||1999||University of Waterloo, Waterloo, Canada||Biochemistry
|MD||2003||Wayne State University||Medicine
|Residency||2006||UCLA Medical Center||Internal Medicine
|Fellowship||2009||University of Chicago||Hematology/Oncology
|Fellowship||2010||University of Chicago||Advanced Hematology/Oncology
Dr. Catenacci's academic interests include laboratory investigation of cell signaling of normal cells and cancer cells, and the evaluation of novel molecular inhibitory targets based on these signaling pathways, with particular focus on receptor tyrosine kinases such as RON and MET tyrosine kinase. The ultimate goal of his research is to develop novel therapeutic agents to be used for the treatment of gastroesophageal and other malignancies.
Other areas of academic interest include Phase I, II, and III clinical trials, drug development and the validation of molecular markers to be predictive and prognostic of patient outcomes. As such, he is actively involved as principle investigator for various gastrointestinal clinical trials, including the American Research and Recovery Act (ARRA) funded pancreatic cancer trial evaluating a novel Hedgehog pathway inhibitor combined with gemcitabine chemotherapy. Additionally, Dr. Catenacci is leading the translational laboratory research effort for these clinical trials for the Gastrointestinal Oncology program, in attempt to explain why some patients obtain benefit from novel therapies while others do not.
Ultimately, he is interested in developing novel approaches to best provide personalized cutting edge cancer care for patients, based on the individual molecular characteristics of their cancer cells as well as their normal cells, while taking into account all aspects of the patient as a whole.
Gastrointestinal malignancies, including:esophageal,gastric (stomach), gastrointestinal stromal tumors (GIST), pancreatic, and hepatobiliary (liver, gallbladder, bile duct) ,small bowel,colorectal,
appendiceal, neuroendocrine, and anal cancers.
- Catenacci DVT, Cervantes G, Yala S, Nelson EA, El-Hassani E, Kanteti R, El Dinali M, Hasina R, Brägelmann J, Seiwert T, Rushe M, Browning B, Orozco O, Zhang M, Hession C, Sanicola M, Bailly V, Henderson L, Grushko T, Olopade O, Karrison T, Bang YJ, Kim WH, Tretiakova M, Vokes EE, Frank DA, Kindler HL, Huet H, Salgia R. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Manuscript submitted.
- Catenacci DVT, Salgia R. RON Tyrosine Kinase in Cancer: No Longer MET’s ‘Little Brother’. Manuscript in preparation.
- Stricker T, Catenacci DVT, Seiwert TY. Molecular profiling of cancer – the future of personalized cancer medicine. A primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Seminars in Oncology submitted
- Catenacci DVT, Kozloff M, Kindler HL, Polite B. Towards Personalized Colon Cancer Care in 2010 – Past, Present and Future. Seminars in Oncology submitted.
- Zhang W, Catenacci DVT, Duan S, Ratain MJ. A Survey of the Population Genetic Variation in the Human Kinome. Nature J of Hum Genet Jul 31 2009. PMID 19644514.